Integrating delivery systems and microenvironmental cues to accelerate clinical translation of cardiac reprogramming.

Boram Son¹, Gwang Yeol Park², Ildoo Jeong^3,4, Hwanhui Kim², Jinkyu Lee², Jinmyoung Joo⁵, Wonhwa Lee⁶, Hee Ho Park²

¹Department of Integrative Biotechnology, Kookmin University, Seoul, 02707, South Korea.

²Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, 02841, South Korea.

³SIMPLE Planet Inc., Seoul, 08390, South Korea.

⁴School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, South Korea.

⁵Department of Biomedical Engineering, Ulsan National Institute of Science and Technology, Ulsan, 44919, South Korea.

⁶Department of Chemistry, Sungkyunkwan University, Suwon, 16419, South Korea.

PubMed PMC DOI PDF

Abstract

Direct cardiac reprogramming, which converts cardiac fibroblasts into functional cardiomyocytes, has emerged as a promising regenerative strategy for heart failure. Preclinical studies have demonstrated its potential to mitigate adverse remodeling; however, critical challenges remain in delivery precision, reprogramming efficiency, and scalability for clinical translation. Here, we review innovati…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.